Russell is a Managing Director of Prospect
Venture Partners. Russell co-founded Prospect Venture Partners
II and III, as dedicated life science funds with over $1 billion
in capital under management. Prior to establishing Prospect
Venture Partners II and III, Russell was a member of the Health
Care Technology Group at Mayfield. He joined Mayfield in 1992,
served as a Venture Partner from 1993 to 1994 and as a General
Partner from 1995-2000. Russell played a key role in Mayfield's
investment activities in the biotechnology and medical device
sectors. As an Associate, he participated actively in the
incubation of Millennium Pharmaceuticals (acquired by Takeda) and as a General
Partner he was responsible for the incubation of Intuitive
Surgical Devices (NASDAQ:ISRG).
Prior to Mayfield, Russell was at the University of California
San Francisco from 1984-1992 where he was engaged in biomedical
research. His work, published in a variety of respected
journals, focused on important aspects of hepatitis B viral
replication. His descriptions of the reverse transcription and
packaging functions of polymerase gene products merited
publication in Nature.
Russell serves or has served on the Board of Directors of Intuitive
Surgical (NASDAQ: ISRG), Hansen Medical (NASDAQ: HNSN), Opus Medical
(NASDAQ: ARTC), Orquest (NASDAQ: JNJ), AVEO Pharmaceuticals (NASDAQ: AVEO),
Visiogen (NYSE: ABT acquired), Baxano, DFine, SentreHEART, NinePoint Medical,
Portola Pharmaceuticals and several other privately-held companies. Russell
served as the Vice Chairman of the BOD of Interplast and on the Genetics
Advisory Council of the Harvard Medical School-Partners Healthcare Center
for Genetics and Genomics.
Russell holds an M.D. and Ph.D. in Biochemistry from the
University of California, San Francisco and a B.A. in Chemistry
from the University of Chicago.